Key Points Two prognosticators published updates on the biotech after it announced a major acquisition. It should soon be the owner of fellow European biotech Merus. 10 stocks we like better than Genmab A/s › One day after announcing a sizable acquisition, Denmark-based biotech Genmab (NASDAQ: GMAB) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the company, helping push it to a nearly 5% price gain in late-session trading. That figure was many ...